SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research.

Tennessee Oncology started using SOPHiA GENETICS in early 2024, when it began to validate the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™ alongside the SOPHiA DDM™ Hereditary Cancer Solution. As the practice worked with SOPHiA GENETICS throughout the year, it experienced the benefits of utilizing the SOPHiA DDM™ Platform for its next generation sequencing (NGS) testing and today announced it will begin to validate the SOPHiA DDM™ RNAtarget Technology and the SOPHiA DDM™ for Comprehensive Genomic Profiling (CGP) application.

“In our time using SOPHiA DDM™, we have been impressed with the outstanding results and incredible support, allowing us to retain our samples in-house and stay abreast of changing guidelines. The addition of these new applications will help us gain a better understanding of what drives cancers down to a molecular level,” said Thomas Stricker, MD, PhD, Pathology Lab Director, Center for Molecular and Genomic Studies, Tennessee Oncology.

The laboratory at Tennessee Oncology will streamline multiple NGS tests within one end-to-end workflow, allowing for a faster turnaround time and consolidating testing to save sample material. By combining RNA sequencing, CGP, and liquid biopsy testing,SOPHiA DDM™ delivers a comprehensive molecular view of cancer, improving a broader understanding of cancer biology for research that can help to improve future clinical decision-making and treatment planning for complex cancer cases.

“We are excited to expand our support of Tennessee Oncology and its network of oncology practices that are driving the future of community-based cancer care, especially as they bring these sophisticated tests to often underserved communities,” said John Carey, Managing Director, NORAM, SOPHiA GENETICS. “By furthering their research and providing access to advanced cancer testing, Tennessee Oncology is innovating the cancer landscape and improving outcomes for patients in need.”

For more information on how labs can benefit from SOPHiA’s end-to-end workflows across a multitude of applications, visit SOPHiAGENETICS.com, or connect on LinkedIn.